A Phase II Study of the c-Met Inhibitor ARQ 197 in Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Tivantinib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 21 Oct 2013 Planned End Date changed from 1 Dec 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 16 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.